The price of medicines in Trump puts the pharmacy warning to the stampede

Pharmaceutical companies are scrambling to respond to a new warning from US President Donald Trump calling for “binding obligations” to reduce drug prices in the United States.

The White House said on Thursday that President Trump was Messages sent To 17 major pharmaceutical companies that determine the steps you must take to reduce the price of prescribed drugs in the United States to the levels of the “most preferred nation” (MFN) by September 29.

They were told that if they “refuse to progress”, the government will spread every tool in “arsenal to protect American families from continuous abusive drug pricing practices”, without mentioning what these measures could be.

The companies were receiving messages Exhaustedand Amgenand AstrazenecaBoehringer Eselheim, Bristol Mairescapeand Eli LilyEMD serono, RushS genntech, Glyidand GSKand Johnson and Johnsonand Merkand Novartisand Novo Nordskand Vizarand Regeneron and Sanovi.

Health care shares fell on Friday, after the market’s wider losses, as investors charged Trump’s commercial tariffs. Wegovy-Maker Novo Nordis shares decreased by 5 % in trade early in the morning before reducing the losses of 1.3 % trading less at 11:15 am London time (6:15 am East time).

Companies have been informed that they should provide MFN prices for all Medicaid patients and the American health program for low -income patients.

They were also told not to provide medicines to other advanced markets at better prices than those offered in the United States, and that they must sell medicines directly to American patients, and thus get rid of pharmacy Brences known as Pharmacy Advantages Directors (PBMS).

Trump has long reduced pharmaceutical companies to what he describes as unfair pricing practices, saying that he intends to reduce US prices by 80 %.

In May, the president signed an executive order on Reduced drug costs By linking the prices of some drugs in the United States to much less than the drugs abroad under MFN policy.

US Pay more constantly in the world For many prescribed medications, this is partly due to the very complex and partial payment system in the United States and the lack of national pricing.

The last announcement comes because the pharmaceutical industry is also Call to clarity On potential definitions at the level of industry. Trump has previously warned that this could reach 200 %.

Several companies have participated with that they agreed with some Trump’s concerns.

The CEO of Astrazeneca Pascal Soriot said on Tuesday that the Swedish company was the Swedish company Contact closely With the American administration on MFN policy and investment in the United States on a broader scale. Last week, it announced plans to invest 50 billion dollars in the United States, after a large number of other pharmaceutical companies.

“There are issues about prices. I personally think the president is right to say that the price equation must occur,” Soreut told reporters in a profit call.

Fez Narayimham, CEO of Novartis, said its Swiss headquarters, said last month that the company is following the MFN policy to reduce the prices of medicines in the United States.

Meanwhile, a novo Nordisk spokesman said that the company “focuses on improving the patient’s access and the ability to withstand costs” and that it “will continue to work to find solutions that help people reach the medicine they need.”

JPMorgan analysts said in a memorandum on Friday that although the last announcement was aimed at a flagrant warning, the ongoing talks between the American administration can buy pharmaceutical companies at some point to respond.

“Although the latest government’s announcement may seem harsh, it is likely that the matter will be somewhat discussed between companies and the government, and we believe that it will not have a significant negative impact on pharmaceutical companies in the short term,” said analysts, led by Segi Wako.